D.C. Lung Cancer Conference 2025

Saturday, October 4, 2025, 7:30 AM - 5:31 PM, JW Marriott, Washington, DC

This one-day multidisciplinary conference will provide a comprehensive update on recent clinical advances in lung cancer. The field is evolving very rapidly and over the past few years, there have been major shifts in our understanding of this highly lethal disease. We have seen high impact advances in all aspects of lung cancer management: from detection to diagnosis to treatment. The D.C. Lung Cancer Conference will emphasize current best practices for busy clinicians who care for patients with lung cancer, across disciplines. High impact, engaging didactic lectures will be delivered by international thought leaders and well-respected faculty in each field. An opening talk from a patient advocate will provide an important perspective. There will be updates on CT screening, proper use of liquid biopsy, interpretation of molecular testing results and review of smoking cessation techniques. A section will be dedicated to optimizing multidisciplinary care for early stage and locally advanced lung cancer to include discussions on minimally invasive surgery and both neoadjuvant and adjuvant systemic therapy, including targeted agents and immunotherapy. Additional sessions will discuss the optimal management of specific molecular subsets of lung cancer, highlighting all currently approved agents. Each session will include a detailed case discussion. Attendees will have the opportunity to interact with faculty in frequent Q&A sessions with access to presentation materials for later review.

All proceeds from the 2025 D.C. Lung Cancer Conference will be used to benefit the Lung Cancer Care Research Fund.

 

Proudly Endorsed by 

1. Identify the survival benefit of CT screening for lung cancer.
2. Describe the methods used for biomarker testing in lung cancer.
3. Explain the approved use of neoadjuvant and perioperative immunotherapy for patients with resectable lung cancer.
4. Debate the use of targeted therapy for patients with resected EGFR mutant non-small cell lung cancer.
5. Describe the best initial therapy for advanced small cell lung cancer (SCLC).
6. Discuss management of immune-mediated toxicities.
7. Discuss standard targeted agents in use for patients with ALK-positive non-small cell lung cancer.
8. Explain the approved use of targeted therapy for KRAS-mutant non-small cell lung cancer.
9. Name the approved targeted agent for HER2 mutant NSCLC.

Early Bird Rate NOW through June 6

• Physician $200

• IASLC Member $160

• Resident/Fellow $0

• Physician Assistant $125

• Nurse Practitioner $125

• Nurse $125

• Allied Health Professional $125

• Pharmacist $125

• Industry Professional  $275

Advanced Purchase and Onsite Rate June 7 to October 4

• Physician $225

• IASLC Member $185

• Resident/Fellow $0

• Physician Assistant $150

• Nurse Practitioner $150

• Nurse $150

• Allied Health Professional $150

• Pharmacist $150

• Industry Professional  $300

Please contact [email protected] or (833) 731-1273 for registration assistance

 In support of improving patient care, MedStar Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

 

Credit Designation Statement

This activity was planned by and for the healthcare team and learners will receive 7.0 Interprofessional Continuing Education (IPCE) credits for learning and change.

 

 

Physicians: MedStar Health designates this live activity for a maximum of 7.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

American Board of Internal Medicine MOC Credit

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 7.0 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

MOC Participation Threshold
Learner participates by writing a reflective statement and makes a commitment to change or maintain an element of practice.

Nurses: This activity is approved for 7.0 ANCC contact hours, which includes 1.5 pharmacotherapeutic contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacists: This activity is approved for 7.0 contact hours. This learning activity is knowledge-based. The Universal Activity Number for this program is JA4008151-0000-25-114-L05-P.

AMA PRA Category 1 Credits™ Physician (7.00 hours), ABIM MOC Part 2 (7.00 hours), IPCE (7.00 hours), Non-Physician Member of the Healthcare Team (7.00 hours), Nurse - ANCC (7.00 hours), Pharmacist - ACPE (7.00 hours)

You are not logged in.

Please click the button below to login or create a new account before continuing.

JW Marriott

1331 Pennsylvania Avenue NW

Washington, DC 20004

Reservation line: 800-393-2503

Mitigation of Relevant Financial Relationships

MedStar Health adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education.

Individuals in a position to control the content of this CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible companies. An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All of the relevant financial relationships listed below have been mitigated prior to the commencement of the activity.

Saturday, October 4, 2025

If you are interested in supporting the program, please contact Elizabeth Romano at [email protected]